## OPEN Case Report

## The Management of an Open Biopsy Tract Site Infection and Ulceration in the Setting of Osteosarcoma

Stephen Bowen, MD Eric Lepkowsky, MD Fazel Khan, MD

From the Department of Orthopaedics, Stony Brook Medicine, Stony Brook, NY.

Correspondence to Dr. Bowen: snbowen3@gmail. com

None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Dr. Bowen, Dr. Lepkowsky, and Dr. Khan.

Dr. Bowen was a major contributor in review of the literature and in writing the manuscript. Dr. Lepkowsky was a major contributor in review of the literature and in writing the manuscript. Dr. Khan performed the surgical intervention and was the primary investigator for the report. All authors read and approved the final manuscript.

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

All data underlying the results are available as part of the article and no additional source data are required.

JAAOS Glob Res Rev 2022;6: e22.00038

DOI: 10.5435/JAAOSGlobal-D-22-00038

Copyright 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### ABSTRACT

Biopsy site infection in the setting of osteosarcoma is a potentially devastating complication. We present the case of a 16-year-old adolescent girl with a distal femur osteosarcoma who developed an open biopsy site ulceration and infection after initiation of neoadjuvant chemotherapy. This was treated with careful local excision of the ulcerated biopsy site and systemic antibiotic therapy throughout the duration of her chemotherapy course. She subsequently underwent wide resection of the tumor en bloc with a generous ellipse around the biopsy scar and reconstruction with cemented knee megaprosthesis. No recurrence of either infection or malignancy was observed. This case represents the successful treatment of a biopsy site ulceration and infection in a patient with osteosarcoma and may merit adoption in future instances of this complication.

steosarcomas are aggressive primary bone tumors, representing approximately 2% of all pediatric cancers.<sup>1</sup> Advancements in medical and surgical management have drastically improved survival and enabled limb-sparing surgery (LSS) in most cases.<sup>2,3</sup> Prompt diagnosis and treatment is necessary to take advantage of these more updated strategies.

Definitive diagnosis by biopsy is required before initiating treatment.<sup>4</sup> Complications after biopsy are rare and usually minor; however, some biopsy complications have devastating sequelae. For example, inappropriately performed biopsies can cause undesired extensive local tumor contamination, potentially compromising limb salvage options.<sup>5</sup> In addition, a biopsy site infection or any infection during chemotherapy can be catastrophic, increasing the likelihood of amputation over limb salvage and decreasing survival because of chemotherapy delays.<sup>4,6,7</sup> Thus, it is critical to treat any infection quickly and aggressively.

There is a paucity of information regarding infected biopsy sites and their management in the setting of osteosarcoma. We present a case of a 16-year-old adolescent girl with distal femur osteosarcoma who developed a biopsy site infection and was successfully treated with no long-term complications and no recurrence of either infection or osteosarcoma.

#### **Case Presentation**

The patient is a 16-year-old adolescent girl who developed left knee pain after falling off a trampoline. A radiograph of the left knee demonstrated a destructive lesion within the distal femur (Figure 1). Chest CT, bone, and MRI scans of the femur were obtained (Figure 1). MRI and bone scans demonstrated a distal femoral lesion concerning for malignancy. Chest CT revealed multiple nodules throughout bilateral lungs, which was concerning for metastases.

She underwent open biopsy of the femur lesion the week of initial presentation. The biopsy was done through a longitudinal (lateral) incision, and strict biopsy principles were adhered to. Cefazolin was given after intraoperative cultures were obtained. Pathologic analysis confirmed diagnosis of chondroblastic osteosarcoma, and the patient was initiated on chemotherapy protocol AOST06P1 (Figure 2) on postoperative day 15.<sup>8</sup> The patient was seen 10 days after surgery, and the biopsy site was found to be healing without any complications. She was cleared for initiation of chemotherapy the following week.

During week 2 of chemotherapy, erythema was noted around the biopsy site with a 1.5-cm ulcer at its distal aspect. The patient was found to be febrile to 38.2°C with an absolute neutrophil count of 45 cells/µL. Vancomycin and cefepime were initiated, and chemotherapy was paused to allow the absolute neutrophil count to normalize. Owing to persistent erythema and ulceration, the patient underwent surgery to address the infected biopsy site. We used an ellipse of the ulcerated area, extending approximately 10 mm away from the incision line  $(3 \times 2 \text{ cm})$  where healthy skin tissue was noted. Cultures were obtained. Gentle irrigation was done with a handheld bulb syringe, and great care was taken to avoid undermining the surrounding tissue. Meticulous hemostasis was again obtained. A negative pressure wound therapy (NPWT) sponge was placed. The wound cultures grew pan-sensitive Pseudomonas aeruginosa. She returned to the operating room 2 days later for staged closure with the plastic surgery team. The closure was done in a layered fashion: 3-0 interrupted braided suture for the fascia, 3-0 interrupted monofilament for the dermis, and a 3-0 running subcuticular monocryl layer. A drain was placed at this time





**A**, AP radiograph of the patient's left knee. **B**, Lateral radiograph of the patient's left knee. **C**, Coronal MRI cuts of the patient's left knee. **D**, Sagittal MRI cuts of the patient's left knee. **E**, Whole body bone scan of the patient with increased uptake in the left knee.

#### Figure 2




Diagram showing the original chemotherapy protocol AOST06P1.

longitudinally in line with the incision. This was removed 2 days later. On discharge, she was transitioned from intravenous antibiotics to oral sulfamethoxazoletrimethoprim, which was intermittently replaced with intravenous cefepime during methotrexate administrations to avoid folate depletion.


This regimen continued until planned wide resection of the tumor, which included the infected biopsy tract. An exceptionally wide ellipse was used to excise the biopsy tract and drain the site, given the history of infection and repeat surgery with possible contamination. This extended several centimeters in all directions and was beveled away from the site to ensure wide margins were obtained. Wide resection of the tumor was then conducted, with care taken to protect the surrounding neurovascular structures (Figures 3–6).

Reconstruction was done with a cemented knee megaprosthesis, and the plastic surgery team used a gastrocnemius flap to provide soft-tissue coverage (Figure 7). A drain was placed, and intravenous cefazolin was continued until drain removal. Afterward, the patient received oral cefazolin until discharge, at which time the sulfamethoxazole-trimethoprim regimen was resumed. She was maintained in a knee immobilizer postoperatively to facilitate wound healing.

The patient continued with scheduled chemotherapy after resection. There were multiple episodes of neutropenic fever throughout her course during which times sulfamethoxazole-trimethoprim was suspended and replaced with intravenous cefepime, nafcillin, and vancomycin. Blood cultures were negative in all instances. Sulfamethoxazole-trimethoprim was stopped in week 17 because of concerns for allergic reaction causing a rash, and monthly pentamidine infusions were initiated instead. The patient had one additional episode of febrile neutropenia 4 months later with blood cultures positive for *Klebsiella pneumonia*. This was successfully treated with oral ciprofloxacin. She had no subsequent occurrences of febrile neutropenia or presumed sepsis.


The complete antimicrobial course included systemic antibiotics for a total of 41 weeks. She has had no additional concerns for infection. The only additional complication was stiffness of her surgical knee, which required manipulation under anesthesia. Her most recent follow-up, 9 years since resection, demonstrated no

#### Figure 3



Photograph showing the exposure with preservation of neurovascular structures

#### Figure 4



Photograph showing wide resection of the tumor with the arrow denoting large ellipse around the formerly infected biopsy site

#### Figure 5



Photographs showing a resected tumor with surrounding cuff of normal tissue

evidence of disease recurrence and no complications with her reconstruction.

#### Discussion

Osteosarcomas are aggressive primary bone tumors, representing 1.5% to 2.5% of all pediatric cancers.<sup>1</sup> Historical survival was poor, ranging from 10% to 22% at 5 years.<sup>9</sup> Treatment originally consisted of amputation, which was often ineffective because 80% of cases had lung metastasis on presentation.<sup>10</sup> Contemporary treatment of osteosarcoma now consists of neoadjuvant chemotherapy, followed by wide surgical resection and adjuvant chemotherapy.<sup>9</sup> This has allowed for LSS with 5-year survival rates of up to 70%.<sup>9</sup>

A biopsy must be obtained before the initiation of treatment. CT-guided biopsy has an accuracy ranging from 66% to 98%; however, open incisional biopsy remains the benchmark with an accuracy from 91% to 96%.<sup>11</sup> Overall complication rates due to biopsy vary,

#### Figure 6



Photograph showing that wide ellipse was used to excise the site of the infected biopsy tract.

approximately 1% in CT-guided core biopsy and as high as 16% in open biopsy.<sup>12</sup> Common complications include infection, seroma, dehiscence, and hematoma, each of which may predispose for local tumor recurrence.<sup>4,13,14</sup>

Infection is particularly concerning in these patients given their susceptibility and the grave consequences. Intensive chemotherapy, long-term central venous catheters, and large resection voids increase infection risk.<sup>1,6</sup> A concern in these patients is that chemotherapy must often be suspended to successfully clear the infection.<sup>7</sup> This can negatively affect overall survival and increase the necessity of amputation rather than LSS.<sup>1,7</sup>

Biopsy tract or surgical site infections create a more complicated tumor bed and increase the risk of local contamination by spread through surrounding cellulitis or edema and by the tumorigenic effect of many inflammatory markers.<sup>5,15</sup> Because of these risks in our patient, the ulcerated and infected tissue was thoroughly excised. In addition, at the time of wide resection, a wider than normal ellipse around the biopsy site was used to remove any potentially contaminated tissue. During the initial excision of infected tissue, great care was taken to avoid undermining the surrounding area because elevating large flaps or crossing tissue planes is well known to increase the risk of tumor contamination.<sup>16,17</sup>

The use of NPWT in the oncologic setting is controversial. Historically, malignancy has been considered a contraindication to NPWT because it was thought to stimulate tumor growth.<sup>18</sup> However, more recent studies have supported its use, reporting no difference in recurrence-free survival and markedly decreased infection rates when NPWT is used.<sup>19,20</sup> Given the concern for infection in our case and the necessity for timely and

## Figure 7



Photographs showing that a lateral gastrocnemius flap was used by the plastic surgery team for soft-tissue coverage.

effective healing, the decision was made to use a wound VAC.

A large amount of resection void in these cases is often unavoidable because of the magnitude of tissue removal required.<sup>21</sup> Primary closure without addressing this can result in hematoma formation with resultant infection or necrosis of the overlying soft tissue.<sup>22</sup> Addressing this space is thus essential to decrease infection risk, provide adequate coverage of the prosthesis, and support the vascularity of the overlying skin.<sup>23</sup> The decision was made in our case to proceed with aggressive soft-tissue coverage, and lateral gastrocnemius flap transposition was done at the time of reconstruction.

Despite the attempts taken to control the infection in this case, a low threshold was maintained to proceed with amputation, if necessary, to allow resumption of chemotherapy. As stated earlier, it is crucial to minimize chemotherapy delays to increase overall survival.<sup>1,7</sup> It is possible that the infection did result in a degree of local contamination that escaped the initial excision and later wide resection. In this case, our success would likely have been aided by the chemotherapy's effect on residual tumor. However, interestingly, the necrosis rate of the patient's tumor was ultimately found to be 58%, indicating a poor response to the therapy.<sup>24</sup>

Reconstruction options after distal femur osteosarcoma resection include femoral rotationplasty, allograft, distraction osteogenesis, and megaprosthetic reconstruction.<sup>25</sup> After presenting these options to the patient and family, they chose to proceed with megaprosthesis reconstruction. This modality is often chosen because it provides rapid restoration of function and is associated with good long-term outcomes. Unfortunately, deep infection occurs at a higher incidence than with primary arthroplasty (8% to 15% versus 1% to 2%).<sup>26</sup> Local treatment of periprosthetic infection is rarely successful, and revision surgery combined with extended systemic antibiotic therapy is often required.<sup>27</sup> This again reinforces the concept that it is critical to conduct all possible measures to minimize the chances of deep infection.

### Conclusion

Biopsy site infection in the setting of osteosarcoma is a challenging problem with limited treatment recommendations examined in the literature. In our case, a 16-year-old patient with a biopsy site infection was successfully treated with a combination of local excision of the infected area and antibiotic therapy throughout the duration of her chemotherapy course. This resulted in eradication of the infection and a relatively uncomplicated course. We think that for osteosarcoma, continuing antibiotics for the duration of chemotherapy may represent an approach to biopsy site infections that may minimize the risk of deep periprosthetic infection. Additional investigation into this protocol and antibiotic choice is warranted.

#### References

1. Czyzewski K, Galazka P, Zalas-Wiecek P, et al: Infectious complications in children with malignant bone tumors: A multicenter nationwide study. *Infect Drug Resist* 2019;12:1471-1480.

2. Evans DR, Lazarides AL, Visgauss JD, et al: Limb salvage versus amputation in patients with osteosarcoma of the extremities: An update in the modern era using the National Cancer Database. *BMC cancer* 2020;20:995-1011.

3. Saghieh S, Masrouha KZ, Musallam KM, et al: The risk of local recurrence along the core-needle biopsy tract in patients with bone sarcomas. *Iowa Orthop J* 2010;30:80-83.

4. Traina F, Errani C, Toscano A, et al: Current concepts in the biopsy of musculoskeletal tumors: AAOS exhibit selection. *J Bone Joint Surg Am* 2015;97:e7.

5. Pretell-Mazzini J, Barton MD Jr, Conway SA, Temple HT: Unplanned excision of soft-tissue sarcomas: Current concepts for management and prognosis. *J Bone Joint Surg Am* 2015;97:597-603.

6. Nagano S, Yokouchi M, Setoguchi T, et al: Analysis of surgical site infection after musculoskeletal tumor surgery: Risk assessment using a new scoring system. *Sarcoma* 2014;2014:645496.

#### Biopsy Infection in the Setting of Osteosarcoma

7. Lee JA, Kim MS, Kim DH, et al: Postoperative infection and survival in osteosarcoma patients. *Ann Surg Oncol* 2009;16:147-151.

8. Goldsby RE, Fan TM, Villaluna D, et al: Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: A report from the Children's Oncology Group. *Eur J Cancer* 2013;49:2384-2391.

#### 9. Papakonstantinou E, Stamatopoulos A, Athanasiadis DI, et al.: Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis. *J Bone Oncol* 2020;25:100319.

10. Friedman MA, Carter SK: The therapy of osteogenic sarcoma: Current status and thoughts for the future. *J Surg Oncol* 1972;4:482-510.

11. Filippiadis DK, Charalampopoulos G, Mazioti A, Keramida K, Kelekis A: Bone and soft-tissue biopsies: What you need to know. *Semin Intervent Radiol* 2018;35:215-220.

12. Maciel MJ, Tyng CJ, Barbosa PN, et al: Computed tomography-guided percutaneous biopsy of bone lesions: Rate of diagnostic success and complications. *Radiol Bras* 2014;47:269-274.

13. Seng C, Png W, Tan MH: Accuracy of core needle biopsy for musculoskeletal tumours. *J Orthop Surg (Hong Kong)* 2013;21: 92-95.

14. Exner GU, Kurrer MO, Mamisch-Saupe N, Cannon SR: The tactics and technique of musculoskeletal biopsy. *EFORT Open Rev* 2017;2: 51-57.

15. Coffey JC, Wang JH, Smith MJ, Bouchier-Hayes D, Cotter TG, Redmond HP: Excisional surgery for cancer cure: Therapy at a cost. *Lancet Oncol* 2003;4:760-768.

16. Iwamoto Y: Diagnosis and treatment of soft tissue tumors. *J Orthop Sci* 1999;4:54-65.

17. Errani C, Traina F, Perna F, Calamelli C, Faldini C: Current concepts in the biopsy of musculoskeletal tumors. *ScientificWorldJournal* 2013;2013: 538152.

18. Venturi ML, Attinger CE, Mesbahi AN, Hess CL, Graw KS: Mechanisms and clinical applications of the vacuum-assisted closure (VAC) device. *Am J Clin Dermatol* 2005;6:185-194.

# 19. Bedi M, King DM, DeVries J, Hackbarth DA, Neilson JC: Does vacuum-assisted closure reduce the risk of wound complications in patients with lower extremity sarcomas treated with preoperative radiation? *Clin Orthop Relat Res* 2019;477:768-774.

20. Stannard JP, Volgas DA, McGwin G III, et al: Incisional negative pressure wound therapy after high-risk lower extremity fractures. *J Orthop Trauma* 2012;26:37-42.

21. Malawer MM, Price WM: Gastrocnemius transposition flap in conjunction with limb-sparing surgery for primary bone sarcomas around the knee. *Plast Reconstr Surg* 1984;73:741-750.

22. Ogura K, Miyamoto S, Sakuraba M, Chuman H, Fujiwara T, Kawai A: Immediate soft-tissue reconstruction using a rectus abdominis myocutaneous flap following wide resection of malignant bone tumours of the pelvis. *Bone Joint J* 2014;96-B:270-273.

23. Buchner M, Zeifang F, Bernd L: Medial gastrocnemius muscle flap in limb-sparing surgery of malignant bone tumors of the proximal tibia: Mid-term results in 25 patients. *Ann Plast Surg* 2003;51:266-272.

24. Bacci G, Mercuri M, Longhi A, et al: Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. *Eur J Cancer* 2005;41:2079-2085.

# 25. Imanishi J, Tanabe M, Kurihara T, et al: Temporal hemiarthroplasty for distal femoral osteosarcoma in early childhood: A case report. *World J Surg Oncol* 2020;18:280.

26. Fujiwara T, Ebihara T, Kitade K, et al: Risk factors of periprosthetic infection in patients with tumor prostheses following resection for musculoskeletal tumor of the lower limb. *J Clin Med* 2020;9:3133.

27. Jeys LM, Grimer RJ, Carter SR, Tillman RM, Abudu A: Post operative infection and increased survival in osteosarcoma patients: Are they associated? *Ann Surg Oncol* 2007;14:2887-2895.